Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/Health Canada/WIXELA INHUB

Authorized

STANDARD

WIXELA INHUB

Mylan Pharmaceuticals ULC🇨🇦 Health Canada

Approval Date: Jul 4, 2025
Approval ID: 6d8dae2555c76b4b
Company: Mylan Pharmaceuticals ULC
Type: Standard

Approval Details

Approval Id: 6d8dae2555c76b4b
Drug Approval Canada Name: WIXELA INHUB
Product Name: WIXELA INHUB
Status: Marketed
Status Date: 2020-02-13
Original Market Date: 2020-02-13
Din: 02495619
Drug Class: Human
Dosage Form: Powder
Route Of Administration: Inhalation
Schedule: Prescription
Ahfs: 12:12.08.12
Atc Original: R03AK06 SALMETEROL AND FLUTICASONE
Atc Name: r 03 ak 06
Aig Number: 0238341003
Company Name: Mylan Pharmaceuticals ULC
Company Address: 85 Advance Road, Etobicoke, Ontario, Canada, M8Z 2S6

Active Ingredients

FLUTICASONE PROPIONATE

500 MCG / ACT

SALMETEROL (SALMETEROL XINAFOATE)

50 MCG / ACT

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

6d8dae2555c76b4b

Type

Standard

Back to Health Canada Approvals

WIXELA INHUB - Health Canada Drug Approval Details